Hodgkin Lymphoma

Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.

Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.

Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.

Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.

The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.

Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.

Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.

A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.